GlassScriptPhysician profile
Sara Benitez
NPI 1023639200
$3,057.45
in general payments reported to CMS, 2019-2025
22 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $237 · 2023: $418 · 2024: $1,681 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,402.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $352.65 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $339.50 | 2024 | Rystiggo, Zilbrysq, Briviact |
| Tanabe Pharma America, INC. | $324.90 | 2024-2025 | Radicava |
| Takeda Pharmaceuticals U.S.A., INC. | $182.72 | 2024-2025 | Hyqvia |
| Csl Behring | $161.32 | 2024-2025 | Hizentra |
| Alexion Pharmaceuticals, INC. | $138.53 | 2024-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $128.95 | 2024 | Andexxa |
| Acadia Pharmaceuticals INC | $122.41 | 2024 | Nuplazid, Daybue |
| Novartis Pharmaceuticals Corporation | $116.01 | 2024 | |
| Averitas Pharma INC. | $104.41 | 2025 | Qutenza |
| Abbvie INC. | $81.40 | 2024 | |
| Grifols USA, LLC | $62.71 | 2025 | Gamunex-C, Xembify |
| Eisai INC. | $61.28 | 2024 | |
| Genentech USA, INC. | $42.48 | 2025 | Evrysdi |
| Genzyme Corporation | $42.27 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $25.71 | 2025 | Symbravo |
| Catalyst Pharmaceuticals, INC. | $22.05 | 2025 | |
| Springworks Therapeutics, INC. | $20.86 | 2025 | Gomekli |
| Xeris Pharmaceuticals, INC. | $20.24 | 2025 | Keveyis |
| Acorda Therapeutics, INC | $18.40 | 2024 | Inbrija |
| Biogen, INC. | $18.17 | 2024 | Tysabri, Vumerity |
| Janssen Biotech, INC. | $15.13 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Benitez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.